PsychedelicNewsBreaks

TuesdayDec 22, 2020 3:29 pm

PsychedelicNewsBreaks – Rritual Superfoods Inc. Eyes Growing Opportunity in Nascent Functional Mushrooms Market

Rritual, a plant-based consumer brand, is set to take advantage of opportunity as functional mushrooms move mainstream. Within the rapidly emerging functional foods industry, the functional mushrooms sector is projected to increase at a CAGR of 5.6% during 2021–2026 and reach $24.85 billion by the end of the forecast period. “Founded in 2019, Rritual has, to date, brought three mushroom-based products to market and is in the process of developing others. Rritual is working to ensure that its offerings not only augment the physical and psychological condition of consumers but also provide a healthy return for shareholders,” states a recent…

Continue Reading

WednesdayDec 16, 2020 11:04 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Begins Facility Build-Out, Prepares to Apply for Dealer’s Licence

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company, has begun build-out work on the fourth unit in is extraction facility; in addition, the company is preparing to submit application to Health Canada requesting a dealer's licence under the Controlled Drugs and Substances Act (“CDSA”), the government entity that provides the framework for legal access to controlled substances, including the control and regulation of production, distribution and sale of psilocybin. Based on guidelines, a company must have a Health Canada-issued licence in order to conduct business with controlled substances. A license could allow Pure Extracts to procure controlled substances; research…

Continue Reading

TuesdayDec 15, 2020 10:43 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Notes Appreciation for Health Canada Milestone Special Access Programme

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, has voiced its support and appreciation for Health Canada’s recently announced Special Access Programme (“SAP”) for psilocybin-assisted psychotherapy inclusion. The government entity recently announced its intent to revise the SAP and other related regulations to allow limited uses of psilocybin-assisted psychotherapeutic treatments. The SAP revision may open the door to new medical applications in the mental health space and support the progress of advanced research initiatives, including ongoing clinical trials evaluating psilocybin-assisted psychotherapy. The proposed SAP update may also positively…

Continue Reading

MondayDec 14, 2020 10:56 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Joins Forces with Adelia Therapeutics to Potentially Address Treatment Gaps Beyond Major Depressive Disorder

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the close of its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million). “We are thrilled to join forces with Adelia. We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” said Cybin CEO Doug Drysdale. “Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side…

Continue Reading

ThursdayDec 10, 2020 3:09 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Agreement to Acquire Adelia Therapeutics

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt of all applicable regulatory and NEO Exchange Inc. approvals. “We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focus on creating novel…

Continue Reading

ThursdayDec 10, 2020 1:56 pm

PsychedelicNewsBreaks – Rritual Superfoods Inc. Holds Key Certification in Emerging Market

Rritual, a plant-based consumer brand, is a therapeutic foods innovator that is gaining attention as it helps build the emerging new market for healthful mushroom elixirs as a beneficial superfood. On the heels of its initial product launch and after snagging an ECRM Buyer’s Choice Award for its attractive marketing and growing market presence, Rritual has secured organic certification from the U.S. Department of Agriculture (“USDA”). The certification provides “trusted, third-party validation of the quality of Rritual’s products” beyond the unregulated claims of many others featuring “all-natural” ingredients, according to Rritual CEO David Kerbel (https://ibn.fm/DZS67). “We have a premium lineup…

Continue Reading

ThursdayDec 10, 2020 10:09 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Lays Groundwork for Move into World of Psychedelics

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, today announced its engagement of a globally recognized operations, compliance and regulatory consulting firm to advise on the company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (“CDSA”). “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible,” said Pure Extracts…

Continue Reading

WednesdayDec 09, 2020 10:03 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Announces LOI with Owner of PURICA(TM) Brand of Wellness Product

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, recently signed a letter of intent with the Nutraceutical Medicine Company Inc. (“PURICA”). PURICA owns and distributes the PURICA product line of full-spectrum, mushroom-derived wellness products. Pure Extracts anticipates the PURICA brand will support PULL’s expansion into the functional mushroom sector. For the past two decades, PURICA has offered natural and whole food products that are backed by science. The company’s Immune 7 formulation has been the Alive Award gold winner for the best immunity product in Canada two years in a…

Continue Reading

FridayDec 04, 2020 1:28 pm

PsychedelicNewsBreaks – Rritual Superfoods Inc.’s ‘Stamp of Approval’ Reinforces Product Distinction

Rritual, a plant-based consumer brand, is a private company that manufactures premium products including small-batch elixir powders and premium shots made from medicinal mushrooms and adaptogenic herbs. With a mission to help people meet the demands of modern life with style and ease through mushroom adaptogen products, Rritual stands distinct among other brands. A recent article discussing this reads, “Rritual was selected as the runner up for the Buyers Choice Award for its Reishi Relax Elixir, picked by retail buyers from dozens of entries. ‘Retail buyers selected Rritual for the award because our packaging, design and formulation stood out amongst…

Continue Reading

WednesdayDec 02, 2020 10:22 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Announces Working Collaboration with Leading Pharmaceutical Science Inventor

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has announced its partnership with Dr. Alexander MacGregor, a key scientific advisor the company. A renowned expert in pharmaceutical technology and novel drug-delivery systems, MacGregor is a dean of faculty and a distinguished professor of biopharmaceutics and current president of the Toronto Institute of Pharmaceutical Technology (“TIPT “), the premier post-graduate institute of pharmaceutical sciences, technology and research in North America. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which conducts cannabis testing and clinical trials. MacGregor will be working with…

Continue Reading